Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lenamilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : Suzhou Intragrand Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Transpire Bio Licenses PDE4 Inhibitor to Suzhou Intragrand Pharma
Details : Under the licensing agreement, Intragrand has granted Transpire Bio an exclusive license to develop, manufacture, and commercialize ITG-1052 in all territories except China.
Product Name : ITG-1052
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 03, 2025
Lead Product(s) : Lenamilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : Suzhou Intragrand Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Transpire Bio Initiates New Study for Asthma and COPD Inhaled Drug Program
Details : Inhalation therapy program is being investigated as asthma and chronic obstructive pulmonary disease (COPD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRB-1
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Recipharm AB
Deal Size : Undisclosed
Deal Type : Agreement
Transpire Bio Announces Agreement with Recipharm for The Development of An Inhaled Medicine
Details : Recipharm is developing and commercializing inhalation technologies and products in support of the development and advancement of Transpire Bio’s TRB-1 and TRB-2 respiratory products.
Product Name : TRB-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 14, 2022
Lead Product(s) : TRB-1
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Recipharm AB
Deal Size : Undisclosed
Deal Type : Agreement